Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

Share Price is delayed by 15 minutes
Get Live Data
2,209.00    19.00 (0.87%)
Bid:
2,212.00
Ask:
2,214.00
Spread: 2.00 (0.09%)
Market Cap: £22.41b
III Live PriceLast checked at - London Stock Exchange

Intraday 3i Group Share Chart

Q1 Performance update

26 Jul 2017 07:00

RNS Number : 0791M
3i Group PLC
26 July 2017
 

26 July 2017

 

3i Group plc

FY2018 Q1 performance update

 

A busy start to the year with four new Private Equity investments and good portfolio performance

 

· NAV per share of 628 pence and total return of 4.1% at 30 June 2017

 

· Good level of new investment in Private Equity with £276 million invested in Hans Anders and Lampenwelt in the quarter and a further £241 million committed to Formel D and Cirtec

 

· Successful close of two new Infrastructure funds, the 3i Managed Infrastructure Acquisitions Fund and the 3i European Operational Projects Fund

 

 

Simon Borrows, Chief Executive, commented:

 

"This was another good quarter for 3i and our portfolio of international investments is performing well against an improving economic backdrop. We completed or signed four new investments in Germany, the Netherlands and the US and some £250 million of divestments, including the announced sale of Mémora at a significant uplift to its March 2017 value. We also added two new Infrastructure funds, the 3i Managed Infrastructure Acquisitions Fund and the 3i European Operational Projects Fund."

 

 

Private Equity

 

Portfolio performance

The Private Equity portfolio performed well in the quarter. Action continued to see strong earnings growth and cash flow generation. There was robust earnings growth across the portfolio more generally with a good contribution from ATESTEO, Q Holding and Audley Travel, together with strong cash flow generation from Scandlines.

 

Private Equity investments

We completed our investments in Hans Anders (£172 million) and Lampenwelt (£104 million) in May 2017 and Formel D (£136 million) in July 2017. We also announced a c.$136 million investment in Cirtec Medical, a leading provider of outsourced engineering and manufacturing to the medical device sector, which is expected to complete by 30 September 2017.

 

Private Equity realisations

We generated total cash proceeds of £107 million in the quarter from the full realisations of MKM and Dphone at uplifts of 3% and 30% respectively against 31 March 2017 book value.

 

 Realisation proceeds

£m

Full realisations

MKM

70

Dphone

26

Other

11

Total Q1 FY2018 cash proceeds

107

 

We also announced the sale of Mémora on 17 July 2017. This disposal, which is expected to complete by the end of September 2017, will generate proceeds of c.£117 million to 3i. Mémora was valued at £86 million at 31 March 2017 and has been moved to an imminent sales basis at 30 June 2017.

 

 

Infrastructure

 

Our team, which advises 3i Infrastructure plc, is working actively on its more recent acquisitions, including potential follow on investments, and its pipeline of possible new investments. 3i also invested £21 million in the new 3i Managed Infrastructure Acquisitions Fund and committed €40 million to the new 3i European Operational Projects Fund, which achieved its first close in April 2017.

 

 

Top 10 investments by value at 30 June 2017

 

Valuation

Valuation

Valuation

Valuation

Mar-17

Jun-17

basis

currency

£m

£m

Activity in the quarter

Action

Earnings

EUR

1,708

1,835

3i Infrastructure plc

Quoted

GBP

655

658

Ex-dividend date 15 June 2017

Scandlines

DCF

EUR

538

571

Q Holding

Earnings

USD

222

238

Weener Plastic

Earnings

EUR

200

213

Audley Travel

Earnings

GBP

185

194

Basic-Fit

Quoted

EUR

184

182

Hans Anders

Earnings

EUR

-

175

New investment

ATESTEO

Earnings

EUR

160

172

BoConcept

Earnings

DKK

146

156

 

The top 10 investments in this table comprise 71% (31 March 2017: 70%) of the total Proprietary Capital portfolio by value.

 

 

Total return and NAV position

 

The continued weakening of sterling against the euro following the UK General Election in June 2017 contributed to a total foreign exchange gain in the quarter of £68 million. Based on the balance sheet at 30 June 2017, a 1% movement in the euro and US dollar would result in a total return movement of £37 million and £7 million respectively. Altogether the diluted NAV per share increased to 628 pence (31 March 2017: 604 pence) and 609.5 pence following the payment of the FY2017 final dividend.

 

 

Balance sheet and dividend

 

The Group's balance sheet remains well funded. Net cash reduced to £161 million, due to the investment activity in the quarter. Liquidity remained strong at £1,086 million. The £136 million investment in Formel D completed on 17 July 2017 and the 18.5 pence FY2017 final dividend (£178 million) was paid on 21 July 2017.

 

 

Notes

 

1.

Balance sheet values are stated net of foreign exchange translation. Where applicable, the GBP equivalents at 30 June 2017 in this update have been calculated at a currency exchange rate of 1.1388:£1 and $1.2989:£1 respectively. At 30 June 2017, 61% of the Group's net assets were in euro and 12% were in US dollar.

2.

At 30 June 2017 3i had 968.4 million diluted shares.

3.

Action was valued using a post discount run-rate EBITDA multiple of 16.0x based on its run-rate earnings to 19 June 2017, the closest period end to 3i's.

 

 

- ENDS -

 

 

For further information, please contact:

Silvia SantoroInvestor Relations DirectorTel: 020 7975 3258

Kathryn van der Kroft

Communications DirectorTel: 020 7975 3021

 

 

About 3i Group

 

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America. For further information, please visit: www.3i.com

 

All statements in this performance update relate to the three month period ended 30 June 2017 unless otherwise stated. The financial information is unaudited and is presented on 3i's non-GAAP Investment basis in order to provide users with the most appropriate description of the drivers of 3i's performance. Net asset value ("NAV") and total return are the same on the Investment basis and on an IFRS basis. Details of the differences between 3i's consolidated financial statements prepared on an IFRS basis and under the Investment basis are provided in the 2017 Annual report and accounts. There have been no material changes to the financial position of 3i from the end of this quarter to the date of this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSELFWIFWSESW
Date   Source Headline
31st Jan 20254:03 pmRNSTotal Voting Rights
31st Jan 20259:36 amRNSDirector Declaration
30th Jan 20257:00 amRNS3i Group plc - Q3 performance update
6th Jan 20253:40 pmRNSDirector/PDMR Shareholding
3rd Jan 20254:38 pmRNSTotal Voting Rights
2nd Jan 202510:59 amRNSPortfolio Update
10th Dec 202411:21 amRNSBlock listing Interim Review
29th Nov 20243:50 pmRNSTotal Voting Rights
29th Nov 20243:43 pmRNSDirector/PDMR Shareholding
14th Nov 202410:39 amRNSDoc re. Half Yearly Report 2024
14th Nov 20247:00 amRNSResults for the six months to 30 September 2024
1st Nov 20249:17 amRNSDirector/PDMR Shareholding
31st Oct 20243:43 pmRNSTotal Voting Rights
1st Oct 202410:09 amRNSPortfolio Update
30th Sep 20243:45 pmRNSTotal Voting Rights
30th Sep 20243:45 pmRNSDirector/PDMR Shareholding
30th Sep 202410:41 amRNSDirector/PDMR Shareholding
25th Sep 20249:36 amRNSDirector/PDMR Shareholding
24th Sep 20243:05 pmRNSDirector/PDMR Shareholding
24th Sep 20243:02 pmRNSDirector/PDMR Shareholding
24th Sep 20247:00 amRNSUpdate on portfolio and Capital Markets Seminar
2nd Sep 202412:34 pmRNSDirector/PDMR Shareholding
30th Aug 20244:19 pmRNSTotal Voting Rights
1st Aug 202411:53 amRNSDirector/PDMR Shareholding
1st Aug 202411:37 amRNSDirector/PDMR Shareholding
31st Jul 20244:14 pmRNSTotal Voting Rights
22nd Jul 20243:37 pmRNSHolding(s) in Company
19th Jul 20242:22 pmRNSDirector/PDMR Shareholding
18th Jul 20247:00 amRNS3i Group plc FY2025 Q1 performance update
1st Jul 20249:54 amRNSPortfolio Update
28th Jun 20243:01 pmRNSTotal Voting Rights
28th Jun 20242:25 pmRNSDirector/PDMR Shareholding
28th Jun 20241:47 pmRNSDirector/PDMR Shareholding
28th Jun 20248:06 amRNSDirector/PDMR Shareholding
27th Jun 20243:34 pmRNSDirector/PDMR Shareholding
27th Jun 20243:05 pmRNSDoc re. AGM Resolutions
27th Jun 20243:04 pmRNSResult of AGM
27th Jun 20242:23 pmRNSHolding(s) in Company
27th Jun 20247:00 amRNSAGM and portfolio update
25th Jun 20249:27 amRNSHolding(s) in Company
21st Jun 20241:55 pmRNSHolding(s) in Company
7th Jun 202411:17 amRNSBlock listing Interim Review
5th Jun 20246:01 pmRNSDirector/PDMR Shareholding
4th Jun 20249:19 amRNSDirector/PDMR Shareholding
3rd Jun 202412:42 pmRNSDirector/PDMR Shareholding
31st May 20244:58 pmRNSTotal Voting Rights
31st May 20244:57 pmRNSDirector/PDMR Shareholding
31st May 20244:55 pmRNSDirector/PDMR Shareholding
22nd May 20243:32 pmRNSDoc Re: 2024 Notice of AGM
16th May 20243:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.